Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Nanchang UniversityNo recent work listed

Xueqiang Deng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0003-7092; OpenAlex author ID A5034405960, A5045028697. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper

Papers 4

  1. SLC35F2-SYVN1-TRIM59 axis critically regulates ferroptosis of pancreatic cancer cells by inhibiting endogenous p53. Co-author DOI 10.1038/s41388-023-02843-y↗
  2. E3 ubiquitin ligase UBR5 promotes pancreatic cancer growth and aerobic glycolysis by downregulating FBP1 via destabilization of C/EBPα. Co-author DOI 10.1038/s41388-020-01527-1↗
  3. E3 ubiquitin ligase TRIM29 promotes pancreatic cancer growth and progression via stabilizing Yes-associated protein 1. Co-author DOI 10.1186/s12967-021-03007-w↗
  4. Downregulation of NEAT1 sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine through modulation of the miR-506-3p/ZEB2/EMT axis First author DOI 10.21203/rs.3.rs-86053/v1↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rongfa Yuan · 2 shared papers, 2021–2023 · strength 0.29
  2. Leifeng Chen · 2 shared papers, 2021–2023 · strength 0.29
  3. Yeqing Zou · 2 shared papers, 2020–2021 · strength 0.27
  4. Xiaowei Fu · 2 shared papers, 2020–2021 · strength 0.27
  5. Ben Che · 1 shared paper, 2023 · strength 0.15
  6. Yunyan Du · 1 shared paper, 2023 · strength 0.15
  7. Wenming Zhang · 1 shared paper, 2023 · strength 0.15
  8. Lu Fang · 1 shared paper, 2021 · strength 0.14
  9. Xiaogang Peng · 1 shared paper, 2021 · strength 0.14
  10. Bo Huang · 1 shared paper, 2020 · strength 0.13
  11. Weidong Xiao · 1 shared paper, 2020 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.